Filter clotting with continuous renal replacement therapy in COVID-19

Abstract

Coronavirus disease 2019 (COVID-19) appears to be associated with increased arterial and venous thromboembolic disease. These presumed abnormalities in hemostasis have been associated with filter clotting during continuous renal replacement therapy (CRRT). We aimed to characterize the burden of CRRT filter clotting in COVID-19 infection and to describe a CRRT anticoagulation protocol that used anti-factor Xa levels for systemic heparin dosing. Multi-center study of consecutive patients with COVID-19 receiving CRRT. Primary outcome was CRRT filter loss. Sixty-five patients were analyzed, including 17 using an anti-factor Xa protocol to guide systemic heparin dosing. Fifty-four out of 65 patients (83%) lost at least one filter. Median first filter survival time was 6.5 [2.5, 33.5] h. There was no difference in first or second filter loss between the anti-Xa protocol and standard of care anticoagulation groups, however fewer patients lost their third filter in the protocolized group (55% vs. 93%) resulting in a longer median third filter survival time (24 [15.1, 54.2] vs. 17.3 [9.5, 35.1] h, p = 0.04). The rate of CRRT filter loss is high in COVID-19 infection. An anticoagulation protocol using systemic unfractionated heparin, dosed by anti-factor Xa levels is reasonable approach to anticoagulation in this population.

Keywords: Acute kidney injury; CRRT; CVVH; Continuous venovenous hemofiltration; Coronavirus; End stage renal disease; Hemodialysis; Hemofiltration; Hypercoagulability; SARS; SARS-CoV2; Thrombosis.

Fig. 1

COVID-19 heparin sliding scale doing schedule for continuous renal replacement therapy using anti-factor Xa levels.

Fig. 2

Study design and systemic heparin use while on continuous renal replacement therapy. Among total patients at risk, the percent displayed under Filter Loss 1, 2, and 3 represents the number who lost a filter divided by the total number who entered that period at risk